日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Cohort Study

对于不可切除的中晚期肝细胞癌患者,与乐伐替尼单药治疗相比,计划性一线乐伐替尼给药联合经动脉化疗栓塞治疗具有优势:一项多中心队列研究

Taniki, Nobuhito; Ojiro, Keisuke; Kasuga, Ryosuke; Nakadai, Yukie; Tabuchi, Takaya; Chu, Po-Sung; Usui, Shingo; Hoshi, Hitomi; Kaneko, Fumihiko; Yamaguchi, Akihiro; Koizumi, Jun; Ebinuma, Hirotoshi; Tamura, Masashi; Tsukada, Jitsuro; Inoue, Masanori; Nakatsuka, Seishi; Hasegawa, Yasushi; Abe, Yuta; Kitago, Minoru; Jinzaki, Masahiro; Kitagawa, Yuko; Kanai, Takanori; Nakamoto, Nobuhiro

Gut Microbiota and Interorgan Communication Among the Gut, Brain, and Beyond

肠道菌群与肠道、大脑及其他器官间的通讯

Shigehara, Arina; Kiyohara, Hiroki; Teratani, Toshiaki; Nakamoto, Nobuhiro; Mikami, Yohei; Kanai, Takanori

Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein Levels in Inflammatory Bowel Disease Patients across Racial Groups

评估不同种族炎症性肠病患者血清中富亮氨酸α2糖蛋白水平

Aoki, Yasuhiro; Kiyohara, Hiroki; Sugimoto, Shinya; Yoshimatsu, Yusuke; Nakamoto, Nobuhiro; Taguri, Masataka; Mikami, Yohei; Kanai, Takanori

Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction

评估美沙拉嗪相关过敏反应中药物诱导淋巴细胞刺激试验的效果

Fukasawa, Naoto; Kiyohara, Hiroki; Adachi, Takeya; Sugimoto, Shinya; Yoshimatsu, Yusuke; Murakami, Soichiro; Mizushima, Ichiro; Kaieda, Yuta; Takabayashi, Kaoru; Tsunoda, Junya; Nakamoto, Nobuhiro; Fukunaga, Koichi; Taguri, Masataka; Mikami, Yohei; Kanai, Takanori

Monitoring ferroptosis in vivo: Iron-driven volatile oxidized lipids as breath biomarkers

体内铁死亡监测:铁驱动的挥发性氧化脂质作为呼吸生物标志物

Matsuoka, Yuta; Katsumata, Yoshinori; Chu, Po-Sung; Morikawa, Rei; Nakamoto, Nobuhiro; Iguchi, Kohta; Takahashi, Ken; Kou, Tadayuki; Ito, Ryo; Taura, Kojiro; Yazumi, Shujiro; Terajima, Hiroaki; Honjo, Gen; Ichihara, Genki; Muramoto, Yuki; Sato, Kazuki; Maeda, Rae; Hata, Kazuhiro; Toriu, Naoya; Yanagita, Motoko; Tajima, Masaki; Fagarasan, Sidonia; Yamada, Ken-Ichi; Sugiura, Yuki

Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study

阿特珠单抗联合贝伐珠单抗治疗在初始疾病进展后继续进行:对不可切除肝细胞癌患者的临床获益——一项多中心队列研究

Tabuchi, Takaya; Taniki, Nobuhito; Ojiro, Keisuke; Kasuga, Ryosuke; Nakadai, Yukie; Chu, Po-Sung; Usui, Shingo; Shiba, Shunsuke; Tahara, Toshiyuki; Komatsu, Hirokazu; Fujita, Yuriko; Kaneko, Fumihiko; Hoshi, Hitomi; Yamaguchi, Akihiro; Fukuhara, Seiichiro; Okamura, Yukishige; Kanamori, Hideaki; Ebinuma, Hirotoshi; Tamura, Masashi; Tsukada, Jitsuro; Hasegawa, Yasushi; Abe, Yuta; Kitago, Minoru; Jinzaki, Masahiro; Kitagawa, Yuko; Kanai, Takanori; Nakamoto, Nobuhiro

Immunological mechanisms underlying fibrotic diseases via single-cell technologies

利用单细胞技术揭示纤维化疾病的免疫机制

Koda, Yuzo; Nakamoto, Nobuhiro; Kanai, Takanori

The 2024 diagnostic criteria for primary sclerosing cholangitis

2024年原发性硬化性胆管炎的诊断标准

Naitoh, Itaru; Isayama, Hiroyuki; Akamatsu, Nobuhisa; Mizuno, Suguru; Fujisawa, Toshio; Nakamoto, Nobuhiro; Nakai, Yousuke; Umetsu, Shuichiro; Suzuki, Mitsuyoshi; Yagi, Shintaro; Haga, Hironori; Notohara, Kenji; Sano, Katsuhiro; Tazuma, Susumu; Nakazawa, Takahiro; Tanaka, Atsushi

Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease

自身免疫性肝炎伴代谢功能障碍相关脂肪肝

Takahashi, Atsushi; Ohira, Hiromasa; Abe, Kazumichi; Zeniya, Mikio; Abe, Masanori; Arinaga-Hino, Teruko; Nakamoto, Nobuhiro; Takaki, Akinobu; Kang, Jong-Hon; Joshita, Satoru; Suzuki, Yoshiyuki; Koike, Kazuhiko; Inui, Ayano; Tanaka, Atsushi

The impact of T cells on immune-related liver diseases: an overview

T细胞对免疫相关肝病的影响:概述

Koda, Yuzo; Kasuga, Ryosuke; Taniki, Nobuhito; Kanai, Takanori; Nakamoto, Nobuhiro